Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial

The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial asse...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nephrology, dialysis, transplantation dialysis, transplantation, 2022-06, Vol.37 (7), p.1317-1329
Hauptverfasser:	Herrington, William G, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen, Staplin, Natalie, Preiss, David, Stevens, Will, Wallendszus, Karl, Dayanandan, Rejive, Knott, Carol, Hill, Michael, Emberson, Jonathan, Brenner, Susanne, Cejka, Vladimir, Cheung, Alfred K, Liu, Zhihong, Li, Jing, Chen, Peiling, Hooi, Laiseong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Pontremoli, Roberto, Maggioni, Aldo Pietro, Goto, Shinya, Tomita, Aiko, Deo, Rajat, Tuttle, Katherine, Eilbracht, Jens, Hantel, Stefan, Hopley, Mark, Landray, Martin J, Baigent, Colin, Haynes, Richard, Brueckmann, Martina, Lozano, Francisco Javier Rossello, Sandercock, Peter, Bilous, Rudolf, Herzog, Charles, Whelton, Paul, Wittes, Janet, Bennett, Derrick, Burke, Andy, Brown, Richard, Fletcher, Lucy, Gosling, Hannah, Harding, Emily, Lee, Ryonfa, Murphy, Kevin, Qiao, Yanru, Raff, Rachel, Yu, Hui, Qiao, YanRu, Fajardo-Moser, Marcela, Lorimer, Andrea, Lucci, Donata, Hepditch, Anita, Axler, Amanda, Hao, Dai, Goh, Cheng Beng, Sivanandam, Sarojini, Hashimoto, Akiko, Negoro, Wakako, Tomoko, Morisaki
Format:	Artikel
Sprache:	eng
Schlagworte:	Benzhydryl Compounds - therapeutic use Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - etiology Disease Progression Double-Blind Method Female Glomerular Filtration Rate Humans Kidney Male Original Renal Insufficiency, Chronic - complications Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on renal and cardiovascular disease have not been tested in a dedicated population of people with chronic kidney disease (CKD). The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD. People with or without diabetes mellitus (DM) were eligible provided they had an estimated glomerular filtration rate (eGFR) ≥20 but
ISSN:	0931-0509 1460-2385
DOI:	10.1093/ndt/gfac040